Additional research is needed to determine whether this is due to direct drug effects or underlying patient factors.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.